A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
Nicola Personeni,Silvia Bozzarelli,Tiziana Pressiani,Lorenza Rimassa,Maria Chiara Tronconi,Francesco Sclafani,Carlo Carnaghi,Vittorio Pedicini,Laura Giordano,Armando Santoro +9 more
TL;DR: Assessment of AFP response may be considered as an alternative to RECIST to capture sorafenib activity in HCC and improve prognostic usefulness of imaging-based Response Evaluation Criteria in Solid Tumors.
Journal ArticleDOI
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
Reid W. Merryman,Haesook T. Kim,Pier Luigi Zinzani,Carmelo Carlo-Stella,Stephen M. Ansell,Miguel-Angel Perales,Abraham Avigdor,Ahmad Halwani,Roch Houot,Tony Marchand,Nathalie Dhedin,Willy Lescaut,Anne Thiebaut-Bertrand,Sylvie François,Aspasia Stamatoullas-Bastard,Pierre-Simon Rohrlich,Hélène Labussière Wallet,L. Castagna,Armando Santoro,Veronika Bachanova,Scott C. Bresler,Amitabh Srivastava,Harim Kim,Emily Pesek,Marie J Chammas,Carol Reynolds,Vincent T. Ho,Joseph H. Antin,Jerome Ritz,Robert J. Soiffer,Philippe Armand +30 more
TL;DR: HSCT after PD-1 blockade appears feasible with a low rate of relapse, however, there may be an increased risk of early immune toxicity, which could reflect long-lasting immune alterations triggered by prior PD- 1 blockade.
Journal ArticleDOI
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
Jose Manuel Trigo,Vivek Subbiah,Benjamin Besse,Benjamin Besse,Victor Moreno,Rafael López,María Ángeles Sala,Solange Peters,Santiago Ponce,Cristian Fernandez,Vicente Alfaro,J. Gomez,Carmen Kahatt,Ali Zeaiter,Khalil Zaman,Valentina Boni,Jennifer Arrondeau,Maite Martínez,Jean Pierre Delord,Ahmad Awada,Rebecca Kristeleit,Maria Eugenia Olmedo,Luciano Wannesson,Javier Valdivia,María Jesús Rubio,Antonio Antón,John Sarantopoulos,Sant P. Chawla,Joaquín Mosquera-Martinez,Manolo D'Arcangelo,Armando Santoro,Victor M. Villalobos,Jacob Sands,Luis Paz-Ares +33 more
TL;DR: Lurbinectedin was active as second-line therapy for SCLC in terms of overall response and had an acceptable and manageable safety profile.
Journal ArticleDOI
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
Thomas Yau,Yoon-Koo Kang,Tae-You Kim,Anthony B. El-Khoueiry,Armando Santoro,Bruno Sangro,Ignacio Melero,Masatoshi Kudo,Ming-Mo Hou,Ana Matilla,Francesco Tovoli,Jennifer J. Knox,Aiwu Ruth He,Bassel F. El-Rayes,Mirelis Acosta-Rivera,Jaclyn Neely,Yun Shen,Carlos Baccan,Christine Dela Cruz,Chiun Hsu +19 more
TL;DR: NIVO monotherapy (mono) is approved for sorafenib (SOR)-treated pts with HCC based on data from CheckMate 040 (NCT01658878), which reported an objective response rate (ORR) of 14% a...
Journal ArticleDOI
Second malignancies in Hodgkin's disease: a complication of certain forms of treatment.
Pinuccia Valagussa,Armando Santoro,Rado Kenda,F Fossati Bellani,F Franchi,Alberto Banfi,Franco Rilke,G. Bonadonna +7 more
TL;DR: The highest incidence of leukaemia occurred after treatment with extensive RT plus MOPP; hence the benefits of this approach in Hodgkin's disease must be weighed against its carcinogenic potential.